Convagran 50 mg 30 capsules

Tradename

Convagran

Convagran

Composition

Each capsule contains:

Zonisamide 50 mg

Auxiliary components:

hydrogenated vegetable oil; MCC; sodium lauryl sulfate.

Capsule shell: gelatin; titanium dioxide (E 171); iron dye black oxide (El 72); dye red charming (E 129); dye sunset yellow (E 110), ink 1014 Tekprint SW-9008 (shellac, propylene glycol, potassium hydrochloride, iron dye black oxide

(E172)

Properties

Zonisamide is an antiepileptic agent derived from benzisoxazole; in vitro it weakly inhibits carbonic anhydrase. Chemically, its structure differs from other antiepileptic drugs.

The mechanism of action of zonisamide is n fully understood, it probably blocks voltagesensitive sodium and calcium channels,

reduces the severity of synchronized neuronal excitation, inhibits the development of seizures and prevents further spread of epileptic activity. Zonisamide also reduces the seizure activity of neurons by increasing the inhibitory effect of GABA.

Indications

-monotherapy in adult patients with partial epileptic seizures with or without secondary generalization, with newly diagnosed epilepsy;

— as part of additional therapy in adults, adolescents and children from 6 years of age with partial epileptic seizures with or without secondary generalization.

Method of administration and dosage:

Contraindications

Hypersensitivity to drug components or sulfonamides. Not recommended:

-With children under 18 years of age;

-With severe liver failure;

Side effects

Convagran@ contains a sulfonamide group. Serious adverse reactions from the immune system associated with taking drugs that contain a sulfonamide group include the appearance of a skin rash and other allergic reactions, as well as the development of severe hematological disorders, including aplastic anemia, in very rare cases leading to fatal the outcome.

The most common adverse reactions in controlled studies of combination therapy were drowsiness, dizziness, and anorexia. The most common adverse reactions in a randomized controlled trial of zonisamide monotherapy versus sustained-release carbamazepine in the zonisamide group were decreased bicarbonate levels, loss of appetite, and weight loss.

Storage method: